COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,610 Articles (22,913 medRxiv, 8,697 bioRxiv)

Most recent first Previous |  Page 1661: Articles 16601-16610  | Next

LRR protein RNH1 inhibits inflammasome activation through proteasome-mediated degradation of Caspase-1 and is associated with adverse clinical outcomes in COVID-19 patients.
Bombaci, G., Sarangdhar, M. A., Andina, N., Tardivel, A., Yu, E. C.-W., Mackie, G. M., Pugh, M., Ozan, V. B., Banz, Y., Spinetti, T., Hirzel, C., Youd, E., Schefold, J. C., Taylor, G. S., Gazdhar, A., Bonadies, N., Angelillo-Scherrer, A., Schneider, P. S., Maslowski, K. M., Allam, R.
10.1101/2021.04.12.438219 — Posted: 2021-04-12
Epitope profiling of coronavirus-binding antibodies using computational structural modelling
Robinson, S. A., Raybould, M. I. J., Marks, C., Schneider, C., Wong, W. K., Deane, C. M.
10.1101/2021.04.12.439478 — Posted: 2021-04-12
Interactions between SARS-CoV-2 N-protein and α-synuclein accelerate amyloid formation
Semerdzhiev, S., Fakhree, M. A. A., Segers-Nolten, I., Blum, C., Claessens, M. M. A. E.
10.1101/2021.04.12.439549 — Posted: 2021-04-12
Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by the broad-spectrum anti-infective drug nitazoxanide
Riccio, A., Santopolo, S., Rossi, A., Piacentini, S., Rossignol, J.-F., Santoro, M. G.
10.1101/2021.04.12.439201 — Posted: 2021-04-12
An AI-guided invariant signature places MIS-C with Kawasaki disease in a continuum of host immune responses
Sahoo, D., Dattatray, G., Shimizu, C., Kim, J., Khandelwal, S., Tremoulet, A. H., Kanegaye, J., Bocchini, J., Das, S., Burns, J. C., Ghosh, P., Pediatric Emergency Medicine Kawasaki Disease Research Group
10.1101/2021.04.11.439347 — Posted: 2021-04-12
Expression of the ACE2 virus entry protein in the nervus terminalis suggests an alternative route for brain infection in COVID-19
Bilinska, K., von Bartheld, C. S., Butowt, R.
10.1101/2021.04.11.439398 — Posted: 2021-04-12
Prediction and evolution of the molecular fitness of SARS-CoV-2 variants: Introducing SpikePro
Pucci, F., Rooman, M.
10.1101/2021.04.11.439322 — Posted: 2021-04-12
Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies
Chen, J., Gao, K., Wang, R., Wei, G.-W.
10.1101/2021.04.12.439473 — Posted: 2021-04-12
Combinatorial approach with mass spectrometry and lectin microarray dissected glycoproteomic features of virion-derived spike protein of SARS-CoV-2
Hiono, T., Tomioka, A., Kaji, H., Sasaki, M., Orba, Y., Sawa, H., Kuno, A.
10.1101/2021.04.10.439300 — Posted: 2021-04-12
Development of highly potent neutralising nanobodies against multiple SARS-CoV-2 variants including the variant of concern B.1.351
Sziemel, A. M., Hwa, S.-H., Sigal, A., Tyson, G., Logan, N., Willett, B. J., Durcan, P. J.
10.1101/2021.04.11.439360 — Posted: 2021-04-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).